Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential

132

Molecular design of a therapeutic LSD analogue with reduced hallucinogenic potential

Tags:

Previous Article

Interplay between mesothelial and immune cells in the tumor microenvironment

LSD analogue with potential for treating schizophrenia

Related Posts

Gut microbiota and eating behaviour in circadian syndrome

Gut microbiota and eating behaviour in circadian syndrome

119

Force and the α-C-terminal domains bias RNA polymerase recycling

Force and the α-C-terminal domains bias RNA polymerase ...

152

Tak1 licenses mitochondrial transfer from astrocytes to POMC neurons to maintain glucose and cholesterol homeostasis

Tak1 licenses mitochondrial transfer from astrocytes to...

96